Gossamer Bio, Inc. (GOSS) Financials
Annual revenue, profitability and per-share results for Gossamer Bio, Inc., as reported in SEC filings.
Revenue • FY2025
$48.47M
▼ 57.7%YoY
Net income • FY2025
-$170.37M
▼ 201.4%YoY
Diluted EPS • FY2025
$-0.75
▼ 200.0%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $48.47M | -$170.37M | — | $-0.75 | -$171.34M | -352.2% | -57.7% |
| FY2024 | $114.7M | -$56.53M | — | $-0.25 | -$3.47M | -52.2% | — |
| FY2023 | $0 | -$179.82M | — | $-1.18 | -$159.16M | — | — |
| FY2022 | $0 | -$229.38M | — | $-2.71 | -$187.44M | — | — |
Figures as reported in Gossamer Bio, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a GOSS filing.
Get an email when GOSS files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.